0001437749-24-026718 | 10-Q | XBRL Viewer

Schedule of Finite-Lived Intangible Assets [Table Text Block]

	June 30,			December 31,
	2024			2023
Patents	$	1,400,000		$	1,400,000
Website development costs		12,007			12,007
Accumulated amortization		(628,976	)		(587,662	)
Net intangible assets	$	783,031		$	824,345

Note 4 - Intangibles

6 Months Ended

Jun. 30, 2024

Intangible Assets Disclosure [Text Block]

Note 4 – Intangibles

The following table sets forth patents and other intangibles:

	June 30,			December 31,
	2024			2023
Patents	$	1,400,000		$	1,400,000
Website development costs		12,007			12,007
Accumulated amortization		(628,976	)		(587,662	)
Net intangible assets	$	783,031		$	824,345

The patents were obtained with the September 30, 2016 reverse acquisition of the 3DIcon Corporation. Amortization expense for the next five fiscal years and thereafter is expected to be approximately $80,000 annually through the year ended December 31, 2034.

Note 6 - Debt (Tables)

6 Months Ended

Jun. 30, 2024

Schedule of Long-Term Debt Instruments [Table Text Block]

	June 30,			December 31,
	2024			2023
Notes payable:
8.29% Insurance premium finance agreement due June 2024	$	-		$	95,376
Current portion of long term debt		1,485,617			476,075
Notes payable - current	$	1,485,617		$	571,451

Long term debt:
10% promissory note, principal payments start July 2024	$	1,346,075		$	1,485,617
8% related party promissory note, due December 2025		250,000			-
Less:
Current portion of long term debt		(1,485,617	)		(476,075	)
Warrants issued		-			(1,688	)
Debt issuance costs		-			(4,038	)
Total long term debt	$	389,542		$	1,003,816

Schedule of Maturities of Long-Term Debt [Table Text Block]

Year	Principal payments due
2024		476,075
2025		870,000
2026		139,542
	$	1,485,617

Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(22))
-SubTopic 10
-Topic 210
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 69B
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B

Reference 3: http://www.xbrl.org/2003/role/exampleRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 69E
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E

Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.12-04(a))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3

Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 835
-SubTopic 30
-Name Accounting Standards Codification
-Section 45
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482925/835-30-45-2

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-3

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 942
-SubTopic 470
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477734/942-470-50-3

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 8
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-8

Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-6

Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-7

+ Details

Note 1 - Business Organization, Nature of Business and Basis of Presentation

6 Months Ended

Jun. 30, 2024

Business Description and Basis of Presentation [Text Block]

Note 1 – Business Organization, Nature of Business and Basis of Presentation

Nature of Business

The Coretec Group Inc. (the “Group”) (formerly 3DIcon Corporation) (“3DIcon”) was incorporated on August 11, 1995, under the laws of the State of Oklahoma as First Keating Corporation. The articles of incorporation were amended August 1, 2003 to change the name to 3DIcon Corporation. During 2001, First Keating Corporation began to focus on the development of 360-degree holographic technology. From January 1, 2001, 3DIcon’s primary activity has been the raising of capital in order to pursue its goal of becoming a significant participant in the development, commercialization and marketing of next generation 3D display technologies.

Coretec Industries, LLC (“Coretec”), is a wholly owned subsidiary of the Group (collectively the “Company”). The Company is currently developing, testing, and providing new and/or improved technologies, products, and service solutions for energy-related industries including, but not limited to oil/gas, renewable energy, and distributed energy industries. Many of these technologies and products also have application for medical, electronic, photonic, display, and lighting markets among others. Early adoption of these technologies and products is anticipated in markets for energy storage (Li-ion batteries), renewable energy (BIPV), and electronics (Asset Monitoring).

Reverse Acquisition

On May 31, 2016, the Group entered into a Share Exchange Agreement (the “Share Exchange Agreement”) with Coretec and four Coretec members (the “Members”), which Members held all outstanding membership interests in Coretec. On September 30, 2016 (the “Closing Date”), the Group closed the transaction contemplated by the Share Exchange Agreement. Pursuant to the Share Exchange Agreement, the Members agreed to sell all their membership interests in Coretec to the Group in exchange for the Group’s issuance of an aggregate 4,760,872 shares of the Group’s Series B Convertible Preferred Stock to the Members (the “Exchange”). Coretec became a wholly owned subsidiary of the Group and the former Members beneficially owned approximately 65% of the Group’s common stock on a fully diluted basis on the Closing Date. Upon the closing of the Share Exchange Agreement, two of the Group’s Directors resigned and three new Directors associated with Coretec were nominated and elected, giving control of the board of directors to former Coretec Members.

Basis of Presentation

The accompanying condensed consolidated financial statements of the Company have been prepared without audit pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”). Certain information and footnote disclosures normally included in the consolidated financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted pursuant to such rules and regulations. The Company believes that the disclosures made are adequate to make the information presented not misleading. These condensed consolidated financial statements should be read in conjunction with the Company’s year-end audited consolidated financial statements and related footnotes included in the previously filed Form 10-K, and in the opinion of management, reflects all adjustments necessary to present fairly the consolidated financial position of the Company. The consolidated results of operations for interim periods may not be indicative of the results which may be realized for the full year.

Note 6 - Debt

6 Months Ended

Jun. 30, 2024

Debt Disclosure [Text Block]

Note 6 – Debt

Notes payable and long-term debt consists of the following:

	June 30,			December 31,
	2024			2023
Notes payable:
8.29% Insurance premium finance agreement due June 2024	$	-		$	95,376
Current portion of long term debt		1,485,617			476,075
Notes payable - current	$	1,485,617		$	571,451

Long term debt:
10% promissory note, principal payments start July 2024	$	1,346,075		$	1,485,617
8% related party promissory note, due December 2025		250,000			-
Less:
Current portion of long term debt		(1,485,617	)		(476,075	)
Warrants issued		-			(1,688	)
Debt issuance costs		-			(4,038	)
Total long term debt	$	389,542		$	1,003,816

8.29% Insurance premium finance agreement, due June 2024

The Company entered into an insurance financing agreement in August 2023 totaling $156,806. The monthly payments under the agreement are due in ten installments of $16,283. The Company has made payments on the note of $113,979 and $65,131 as of June 30, 2024 and December 31, 2023, respectively. The Company paid the balance in full during the quarter ended June 30, 2024.

10% Promissory note, principal payments start July 2024

On October 4, 2019, the Company entered into a Credit Agreement and related Promissory Note with Diversified Alpha Fund of Navigator Global Fund Manager Platform SPC (“DAF”), the Lender. DAF is a segregated portfolio fund of Navigator Global Fund Manager Platform SPC. DAF is managed and controlled by Mollitium Investment Management (Mollitium). Mollitium utilizes Diversified Global Investment Advisors Ltd. (“DGIA”) to act in an advisory role. DGIA maintains an Investment Committee to support the services to Mollitium. Simon Calton serves as part of this five-member investment committee and in accordance with the investment committee’s guidelines, Mr. Calton does not participate in matters or voting that pertain to the Company due to his conflict of interest. Investment advice provided by DGIA to Mollitium are recommendations only and the final decision on actions are the responsibility of Mollitium. Carlton James Global Management, Ltd (CJGM) serves as a distributer of investments by introducing funds available to the market of which DAF is included in CJGM’s group of funds. Compensation to CJGM occurs when investments are made into funds that they introduce. CJGM is part of the Carlton James Group of which Mr. Calton is CEO.

The 10% Promissory Note, in a principal amount of $2,500,000, is due on the 15th day of the 4th anniversary of each advance with the first capital payment due on July 15, 2024. The Promissory Note has attached warrants to subscribe for and purchase 3,000,000 shares of common stock at an exercise price of $0.052 per share. Under the terms of the Credit Agreement, DAF will fund the Promissory Note in sixteen (16) tranches in amounts of $125,000 and $175,000 per month beginning in October 2019. The funding of the Promissory Note is at the discretion of DAF and may differ from the planned schedule. As of June 30, 2024, DAF has advanced $2,345,000 with no definitive date or commitment to advance the remaining $155,000. Interest is accrued monthly and paid in advance for the first six months and thereafter interest only payments shall be paid quarterly.

On November 16, 2021, the Company countersigned a letter of variation (the Variation) to the credit agreement entered into on October 4, 2019, with DAF. Pursuant to the Variation, the Lender agreed to extend the repayment days for each advance made by Lender under the credit agreement until the fourth anniversary of such advance. DAF also communicated to the Company that interest only payments are due on a quarterly basis, which commenced in January of 2022.

On May 12, 2023, the Company countersigned a second letter of variation (the Second Variation) to the credit agreement entered into on October 4, 2019, with DAF. Pursuant to the Second Variation, the Lender agreed to extend the repayment days for each advance made by Lender under the credit agreement by an additional four months. The first principal payment will be due on July 15, 2024 with all other terms and conditions of the credit facility remaining unchanged.

Under the terms of the Credit Agreement, DAF has the right to elect to convert all or part of the Promissory Note at a price equal to seventy percent (70%) of the average closing price of the Company’s common stock as reported on the over-the-counter quotation system on the OTC Markets during the fifteen (15) calendar days prior to the loan closing date of October 4, 2019, which calculates to $0.0329 per share.

Under the terms of the Credit Agreement, warrants to subscribe for and purchase 3,000,000 shares of common stock at an exercise price of $0.052 per share were issued to DAF. The estimated value of the warrants granted monthly, with each advance, is calculated using the Black-Scholes option pricing model. The resulting estimated value of the warrant is used to proportionally allocate the fair value of the debt advance and the fair value of the warrants.

Additionally, under the terms of the Credit Agreement, the Company agreed to pay a commitment fee of 3% of each advance and reimburse DAF for certain expenses in connection with the preparation, interpretation, performance and enforcement of the Credit Agreement. Those costs are being amortized over the life of the debt. The Company amortized $1,688 and $8,674 during the six months ended June 30, 2024 and 2023, respectively.

Interest payments were made to DAF of $0 and $68,359 during the six months ended June 30, 2024 and 2023, respectively.

The following table sets forth the DAF principal payment schedule by year:

Year	Principal payments due
2024		476,075
2025		870,000
2026		139,542
	$	1,485,617

8.00% Related party promissory note, principal and interest due December 2025

The Company entered into a convertible promissory note on June 18, 2024 with Mr. Keen. The maturity date of the note is 18 months from the date of issuance. Interest on the unpaid principal balance of the note accrues at 8% per annum, payable on maturity. The note is subject to a mandatory conversion provision if the transaction as reported in the form 8K submitted with the SEC on March 6, 2024, is successfully consummated. On closing of such transaction, the note shall automatically and mandatorily convert into common shares, and the note holder shall be issued warrants purchase up to 78,125,000 shares of common stock of the Company at an exercise price of $0.007. The Warrants shall be exercisable for a period of five (5) years from the date of issuance. Mr. Keen is Co-Chairman of the Board of Directors of the Company.

The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481544/470-10-50-6

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481544/470-10-50-6

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 405
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477092/405-40-50-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 405
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477092/405-40-50-1

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 405
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477092/405-40-50-1

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 405
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477092/405-40-50-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 405
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477092/405-40-50-1

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(c))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 470
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org/470/tableOfContent

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 835
-SubTopic 30
-Name Accounting Standards Codification
-Section 45
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482925/835-30-45-2

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1C
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1C
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1C
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1E
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1I
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1I
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1I
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I

+ Details

Note 8 - Common Stock, Preferred Stock, Warrants, and Options

6 Months Ended

Jun. 30, 2024

Equity [Text Block]

Note 8 – Common Stock, Preferred Stock, Warrants and Options

Common Stock

On June 8, 2020, the Board of Directors consented to a share exchange agreement with holders of 21,500,000 options awarded on August 7, 2019. The agreement allows for holders to exchange their options for rule 144 common stock at an exchange rate of 0.6 shares per 1 option. Under the exchange agreement, 9,500,000 options have been exchanged for 5,700,000 shares of common stock as of June 30, 2024.

On October 27, 2023 the Board of Directors consented to extend the previous practice of satisfying accrued liabilities of vendors by issuing common stock from the equity incentive plans through September 1, 2024. The number of shares issued to satisfy a liability was determined by the average closing price for the fifteen (15) days prior to conversion at a discount rate of 50% to that fifteen (15) day average. The stock issuance, in lieu of cash payment, requires written approval of the Chief Executive Officer. The Company issued 903,224 and 0 shares under this consent for the six months ended June 30, 2024 and 2023, respectively.

Warrants

Warrants to subscribe for and purchase up to 3,000,000 shares of common stock at an exercise price of $0.052 per share were included under the terms of the DAF Credit Agreement. The warrants will be issued in amounts of 150,000 and 210,000 per month during the funding period. In the event that funding advances deviate from the planned schedule then warrants will be issued pro-rata at 1.2 warrants for every $1 of funding. Warrants granted under the terms of the DAF Credit Agreement total 2,814,000 as of June 30, 2024 and December 31, 2023. The estimated value of the warrants granted monthly, with each advance, is calculated using the Black-Scholes option pricing model. The expected dividend yield is based on the average annual dividend yield as of the grant date. Expected volatility is based on the historical volatility of our stock. The risk-free interest rate is based on the U.S. Treasury Constant Maturity rates as of the grant date. The expected life of the warrant is based on historical exercise behavior and expected future experience. the resulting estimated value of the warrant is used to proportionally allocate the fair value of the debt advance and the fair value of the warrants.

On March 2, 2021, the Company entered into the Purchase Agreement with a single institutional investor in a private placement to sell (i) 23,500,000 shares of its common stock, (ii) pre-funded warrants to purchase up to an aggregate of 51,500,000 shares of its common stock, and (iii) warrants to purchase up to an aggregate of 82,500,000 shares of its common stock for gross proceeds of approximately $6,000,000. The combined purchase price for one share of common stock and associated Warrant is $0.08 and for one Pre-Funded Warrant and associated Warrant is $0.0799. The sale of the securities under the Purchase Agreement closed on March 5, 2021. The pre-funded warrants have an exercise price of $0.0001 per share, subject to adjustment as set forth in the pre-funded warrants for stock splits, stock dividends, recapitalizations and similar events. The pre-funded warrants will be exercisable immediately and may be exercised at any time until all of the pre-funded warrants are exercised in full. In addition, the Company agreed to issue to the placement agent (or its designees) warrants to purchase a number of shares equal to 8.0% of the aggregate number of shares and pre-funded warrant shares sold under the Purchase Agreement, or warrants to purchase an aggregate of up to 6,000,000 shares. The placement agent warrants generally will have the same terms as the warrants, except they will have an exercise price of $0.10.

Warrants Summary

The Company did not issue any new warrants for the six months ended June 30, 2024. The following table summarizes the Company’s warrants as of June 30, 2024:

						Weighted
				Weighted		Average
				Average		Remaining		Aggregate
	Number of			Exercise		Life		Intrinsic
	Warrants			Price		In Years		Value

Outstanding, December 31, 2023		120,014,000		$	0.0612		2.63
Exercised		(28,700,000	)		0.0001
Outstanding, June 30, 2024		91,314,000		$	0.0805		2.11	$	-

Options

Stock options for employees, directors or consultants, are valued at the date of award, which does not precede the approval date, and compensation cost is recognized in the period the options are vested. The Company recognizes compensation expense for awards subject to graded vesting on a straight-line basis. Stock options generally become exercisable on the date of grant and expire based on the terms of each grant.

The estimated fair value of options for common stock granted was determined using the Black-Scholes option pricing model. The expected dividend yield is based on the average annual dividend yield as of the grant date. Expected volatility is based on the historical volatility of our stock. The risk-free interest rate is based on the U.S. Treasury Constant Maturity rates as of the grant date. The expected life of the option is based on historical exercise behavior and expected future experience.

The Company recognized $0 of stock option expense during the six months ended June 30, 2024 and 2023.

Options Summary

The following table summarizes the Company’s options as of June 30, 2024:

						Weighted
				Weighted		Average
				Average		Remaining		Aggregate
	Number of			Exercise		Life		Intrinsic
	Options			Price		In Years		Value

Outstanding, December 31, 2023		101,158,160		$	0.059
Options exercised		(3,000,000	)		0.024
Outstanding, June 30, 2024		98,158,160		$	0.060		2.67	$	-

Exercisable, June 30, 2024		98,158,160		$	0.060		2.67	$	-

The following table, based on exercise price, summarizes the Company’s options as of June 30, 2024:

				Weighted
		Outstanding		Average		Exercisable
Exercise		Number of		Remaining Life		Number of
Price		Options		In Years		Options

$	0.024		21,000,000		4.32		21,000,000
$	0.028		24,000,000		3.29		24,000,000
$	0.041		12,500,000		0.10		12,500,000
$	0.055		950,000		2.73		950,000
$	0.065		1,000,000		1.00		1,000,000
$	0.105		38,500,000		2.25		38,500,000
$	0.240		208,160		2.72		208,160
Total			98,158,160		2.67		98,158,160

The entire disclosure for equity.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-14

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 235
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477968/946-235-50-2

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 235
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477968/946-235-50-2

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 505
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478448/946-505-50-6

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480237/815-40-50-6

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(e)(1))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 505
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org/505/tableOfContent

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-14

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-14

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 16
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-16

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 18
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-18

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 18
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-18

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 18
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-18

+ Details

Document And Entity Information - shares	6 Months Ended
Document And Entity Information - shares	Jun. 30, 2024	Aug. 14, 2024
Document Information [Line Items]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Jun. 30, 2024
Document Transition Report	false
Entity File Number	000-54697
Entity Registrant Name	THE CORETEC GROUP INC.
Entity Incorporation, State or Country Code	OK
Entity Tax Identification Number	73-1479206
Entity Address, Address Line One	333 Jackson Plaza, STE 460
Entity Address, City or Town	Ann Arbor
Entity Address, State or Province	MI
Entity Address, Postal Zip Code	48103
City Area Code	866
Local Phone Number	916-0833
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding (in shares)		336,738,361
Entity Central Index Key	0001375195
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2024
Document Fiscal Period Focus	Q2
Amendment Flag	false

Condensed Consolidated Statements of Changes in Stockholders' Equity (Unaudited) - USD ($)	Preferred Stock [Member] Series A Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Balance (in shares) at Dec. 31, 2022	345,000	268,871,202
Balance at Dec. 31, 2022	$ 69	$ 53,772	$ 18,119,792	$ (16,345,313)	$ 1,828,320
Net loss for the period	$ 0	$ 0	0	(507,384)	(507,384)
Balance (in shares) at Mar. 31, 2023	345,000	268,871,202
Balance at Mar. 31, 2023	$ 69	$ 53,772	18,119,792	(16,852,697)	1,320,936
Balance (in shares) at Dec. 31, 2022	345,000	268,871,202
Balance at Dec. 31, 2022	$ 69	$ 53,772	18,119,792	(16,345,313)	1,828,320
Net loss for the period					(981,679)
Balance (in shares) at Jun. 30, 2023	345,000	283,175,872
Balance at Jun. 30, 2023	$ 69	$ 56,633	18,136,268	(17,326,992)	865,978
Balance (in shares) at Mar. 31, 2023	345,000	268,871,202
Balance at Mar. 31, 2023	$ 69	$ 53,772	18,119,792	(16,852,697)	1,320,936
Warrants exercised (in shares)	0	12,500,000
Warrants exercised	$ 0	$ 2,500	(1,250)	0	1,250
Net loss for the period	$ 0	$ 0	0	(474,295)	(474,295)
Common stock issued for liabilities (in shares)	0	1,804,670
Common stock issued for liabilities	$ 0	$ 361	17,726	0	18,087
Stock Issued During Period, Shares, Warrants Exercised (in shares)	0	12,500,000
Stock Issued During Period, Value, Warrants Exercised	$ 0	$ 2,500	(1,250)	0	1,250
Balance (in shares) at Jun. 30, 2023	345,000	283,175,872
Balance at Jun. 30, 2023	$ 69	$ 56,633	18,136,268	(17,326,992)	865,978
Balance (in shares) at Dec. 31, 2023	345,000	284,104,032
Balance at Dec. 31, 2023	$ 69	$ 56,819	18,706,208	(18,652,952)	110,144
Common stock issued for services (in shares)	0	903,224
Common stock issued for services	$ 0	$ 181	8,779	0	8,960
Warrants exercised (in shares)	0	14,861,316
Warrants exercised	$ 0	$ 2,972	(2,972)	0	0
Options exercised (in shares)	0	1,500,000
Options exercised	$ 0	$ 300	(300)	0	0
Net loss for the period	$ 0	$ 0	0	(524,223)	(524,223)
Stock Issued During Period, Shares, Warrants Exercised (in shares)	0	14,861,316
Stock Issued During Period, Value, Warrants Exercised	$ 0	$ 2,972	(2,972)	0	0
Balance (in shares) at Mar. 31, 2024	345,000	301,368,572
Balance at Mar. 31, 2024	$ 69	$ 60,272	18,711,715	(19,177,175)	(405,119)
Balance (in shares) at Dec. 31, 2023	345,000	284,104,032
Balance at Dec. 31, 2023	$ 69	$ 56,819	18,706,208	(18,652,952)	$ 110,144
Options exercised (in shares)					3,000,000
Net loss for the period					$ (858,447)
Balance (in shares) at Jun. 30, 2024	345,000	336,738,361
Balance at Jun. 30, 2024	$ 69	$ 67,346	18,801,033	(19,511,399)	(642,951)
Balance (in shares) at Mar. 31, 2024	345,000	301,368,572
Balance at Mar. 31, 2024	$ 69	$ 60,272	18,711,715	(19,177,175)	(405,119)
Warrants exercised (in shares)		13,680,579
Warrants exercised		$ 2,736	(2,736)
Net loss for the period	$ 0	$ 0	0	(334,224)	(334,224)
Common stock issued for liabilities (in shares)	0	21,689,210
Common stock issued for liabilities	$ 0	$ 4,338	92,054	0	96,392
Stock Issued During Period, Shares, Warrants Exercised (in shares)		13,680,579
Stock Issued During Period, Value, Warrants Exercised		$ 2,736	(2,736)
Balance (in shares) at Jun. 30, 2024	345,000	336,738,361
Balance at Jun. 30, 2024	$ 69	$ 67,346	$ 18,801,033	$ (19,511,399)	$ (642,951)

Note 2 - Summary of Significant Accounting Policies - Estimated Useful Lives (Details)	Jun. 30, 2024
Furniture and Fixtures [Member]
Useful life (Year)	7 years
Equipment [Member]
Useful life (Year)	7 years

Note 2 - Summary of Significant Accounting Policies (Tables)

6 Months Ended

Jun. 30, 2024

Property Plant and Equipment, Estimated Useful Lives [Table Text Block]

Asset Description	Estimated Lives (years)
Furniture and fixtures		7
Laboratory Equipment		7

Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]

	June 30,
	2024		2023
Options		98,158,160		77,158,160
Warrants		91,314,000		120,014,000
Series A convertible preferred stock		115,000		115,000
Convertible debt		123,280,537		45,155,537
Total potentially dilutive shares		312,867,697		242,442,697

Note 4 - Intangibles - Schedule of Patents (Details) - USD ($)	Jun. 30, 2024	Dec. 31, 2023
Accumulated Amortization	$ (628,976)	$ (587,662)
Net intangible assets	783,031	824,345
Patents [Member]
Gross Carrying Amount	1,400,000	1,400,000
Website Development Costs [Member]
Gross Carrying Amount	$ 12,007	$ 12,007

Note 2 - Summary of Significant Accounting Policies - Antidilutive Securities (Details) - shares	6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Potentially dilutive shares (in shares)	312,867,697	242,442,697
Options [Member]
Potentially dilutive shares (in shares)	98,158,160	77,158,160
Warrants [Member]
Potentially dilutive shares (in shares)	91,314,000	120,014,000
Series A Convertible Preferred Stock [Member]
Potentially dilutive shares (in shares)	115,000	115,000
Convertible Debt Securities [Member]
Potentially dilutive shares (in shares)	123,280,537	45,155,537

Note 8 - Common Stock, Preferred Stock, Warrants and Options - Warrants (Details) - USD ($)	6 Months Ended	12 Months Ended
	Jun. 30, 2024	Dec. 31, 2023
Warrants, number (in shares)	120,014,000
Warrants, exercise price (in dollars per share)	$ 0.0612
Warrants, remaining life (Year)	2 years 1 month 9 days	2 years 7 months 17 days
Exercised, number (in shares)	(28,700,000)
Exercised, exercise price (in dollars per share)	$ 0.0001
Warrants, number (in shares)	91,314,000	120,014,000
Warrants, exercise price (in dollars per share)	$ 0.0805	$ 0.0612
Warrants, aggregate intrinsic value	$ 0

Note 8 - Common Stock, Preferred Stock, Warrants and Options - Shares Authorized Under Stock Option Plans (Details)	6 Months Ended
	Jun. 30, 2024 $ / shares shares
Option Outstanding, Number Of Options (in shares)	98,158,160
Option Exercisable, Weighted Average Remaining Life In Years (Year)	2 years 8 months 1 day
Option Exercisable, Number Of Options (in shares)	98,158,160
Exercise Price Range One [Member]
Option Outstanding, Exercise Price (in dollars per share) \| $ / shares	$ 0.024
Option Outstanding, Number Of Options (in shares)	21,000,000
Option Exercisable, Weighted Average Remaining Life In Years (Year)	4 years 3 months 25 days
Option Exercisable, Number Of Options (in shares)	21,000,000
Exercise Price Range Two [Member]
Option Outstanding, Exercise Price (in dollars per share) \| $ / shares	$ 0.028
Option Outstanding, Number Of Options (in shares)	24,000,000
Option Exercisable, Weighted Average Remaining Life In Years (Year)	3 years 3 months 14 days
Option Exercisable, Number Of Options (in shares)	24,000,000
Exercise Price Range Three [Member]
Option Outstanding, Exercise Price (in dollars per share) \| $ / shares	$ 0.041
Option Outstanding, Number Of Options (in shares)	12,500,000
Option Exercisable, Weighted Average Remaining Life In Years (Year)	1 month 6 days
Option Exercisable, Number Of Options (in shares)	12,500,000
Exercise Price Range Four [Member]
Option Outstanding, Exercise Price (in dollars per share) \| $ / shares	$ 0.055
Option Outstanding, Number Of Options (in shares)	950,000
Option Exercisable, Weighted Average Remaining Life In Years (Year)	2 years 8 months 23 days
Option Exercisable, Number Of Options (in shares)	950,000
Exercise Price Range Five [Member]
Option Outstanding, Exercise Price (in dollars per share) \| $ / shares	$ 0.065
Option Outstanding, Number Of Options (in shares)	1,000,000
Option Exercisable, Weighted Average Remaining Life In Years (Year)	1 year
Option Exercisable, Number Of Options (in shares)	1,000,000
Exercise Price Range Six [Member]
Option Outstanding, Exercise Price (in dollars per share) \| $ / shares	$ 0.105
Option Outstanding, Number Of Options (in shares)	38,500,000
Option Exercisable, Weighted Average Remaining Life In Years (Year)	2 years 3 months
Option Exercisable, Number Of Options (in shares)	38,500,000
Exercise Price Range Seven [Member]
Option Outstanding, Exercise Price (in dollars per share) \| $ / shares	$ 0.24
Option Outstanding, Number Of Options (in shares)	208,160
Option Exercisable, Weighted Average Remaining Life In Years (Year)	2 years 8 months 19 days
Option Exercisable, Number Of Options (in shares)	208,160

Note 6 - Debt (Details Textual)			1 Months Ended	6 Months Ended		12 Months Ended	57 Months Ended
Note 6 - Debt (Details Textual)	Jun. 18, 2024 $ / shares shares	Oct. 04, 2019 USD ($) $ / shares shares	Aug. 31, 2023 USD ($)	Jun. 30, 2024 USD ($) $ / shares shares	Jun. 30, 2023 USD ($)	Dec. 31, 2023 USD ($) $ / shares shares	Jun. 30, 2024 USD ($) $ / shares shares
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) \| shares						2,814,000
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) \| $ / shares				$ 0.0805		$ 0.0612	$ 0.0805
Amortization Associated With Commitment Fee				$ 1,688	$ 8,674
Warrant Issued in Connection With Credit Agreement [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) \| shares		3,000,000		2,814,000			2,814,000
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) \| $ / shares		$ 0.052
Convertible Promissory Note Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) \| shares	78,125,000
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) \| $ / shares	$ 0.007
Warrants and Rights Outstanding, Term (Year)	5 years
Insurance Financing Agreement Due June 2024 [Member]
Debt Instrument, Interest Rate, Stated Percentage			8.29%	8.29%		8.29%	8.29%
Debt Instrument, Face Amount			$ 156,806
Debt Instrument, Term			10 months
Debt Instrument, Periodic Payment			$ 16,283
Repayments of Long-Term Debt				$ 113,979		$ 65,131
Credit Agreement And Note [Member]
Debt Instrument, Interest Rate, Stated Percentage		10.00%		10.00%		10.00%	10.00%
Debt Agreement, Maximum Borrowing Capacity		$ 2,500,000
Debt Instrument, Number of Tranches		16
Proceeds from Notes Payable, Total							$ 2,345,000
Debt Instrument, Notes Payable, Portion Not Advanced				$ 155,000			$ 155,000
Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger		70.00%
Debt Instrument, Convertible, Threshold Trading Days		15
Debt Instrument, Convertible, Conversion Price (in dollars per share) \| $ / shares		$ 0.0329
Line of Credit Facility, Commitment Fee Percentage		3.00%
Credit Agreement And Note [Member] \| Minimum [Member]
Debt Instrument, Amount Funded in Each Monthly Tranche		$ 125,000
Credit Agreement And Note [Member] \| Maximum [Member]
Debt Instrument, Amount Funded in Each Monthly Tranche		$ 175,000
DAF Credit Agreement [Member]
Interest Paid, Including Capitalized Interest, Operating and Investing Activities				$ 0	$ 68,359
Convertible Promissory Note June 18, 2024 [Member]
Debt Instrument, Interest Rate, Stated Percentage	8.00%
Debt Instrument, Term	18 months

Note 10 - Subsequent Events

6 Months Ended

Jun. 30, 2024

Subsequent Events [Text Block]

Note 10 – Subsequent Events

Second Amendment to Share Exchange Agreement

As previously disclosed, on March 1, 2024, the Company entered into a Share Exchange Agreement with Core Optics, the Operating Subsidiary and the Member, which Member holds all outstanding membership interests in Core Optics. On June 27, 2024, the Company, Core Optics, the Operating Subsidiary and the Member entered into an Amendment Agreement, pursuant to which Amendment Agreement the parties had agreed to certain amendments to the Share Exchange Agreement, including to extend the final date of the Share Exchange Agreement to July 31, 2024.

On July 31, 2024, the parties entered into the Second Amendment Agreement to further extend the final date of the Share Exchange Agreement, as amended, to August 15, 2024. All parties continue to progress to complete certain pre-closing and closing conditions, under the Share Exchange Agreement and the First Amendment Agreement.

Note 8 - Common Stock, Preferred Stock, Warrants, and Options (Tables)

6 Months Ended

Jun. 30, 2024

Warrant Activity [Table Text Block]

						Weighted
				Weighted		Average
				Average		Remaining		Aggregate
	Number of			Exercise		Life		Intrinsic
	Warrants			Price		In Years		Value

Outstanding, December 31, 2023		120,014,000		$	0.0612		2.63
Exercised		(28,700,000	)		0.0001
Outstanding, June 30, 2024		91,314,000		$	0.0805		2.11	$	-

Disclosure of Share-Based Compensation Arrangements by Share-Based Payment Award [Table Text Block]

						Weighted
				Weighted		Average
				Average		Remaining		Aggregate
	Number of			Exercise		Life		Intrinsic
	Options			Price		In Years		Value

Outstanding, December 31, 2023		101,158,160		$	0.059
Options exercised		(3,000,000	)		0.024
Outstanding, June 30, 2024		98,158,160		$	0.060		2.67	$	-

Exercisable, June 30, 2024		98,158,160		$	0.060		2.67	$	-

Share-Based Payment Arrangement, Option, Exercise Price Range [Table Text Block]

				Weighted
		Outstanding		Average		Exercisable
Exercise		Number of		Remaining Life		Number of
Price		Options		In Years		Options

$	0.024		21,000,000		4.32		21,000,000
$	0.028		24,000,000		3.29		24,000,000
$	0.041		12,500,000		0.10		12,500,000
$	0.055		950,000		2.73		950,000
$	0.065		1,000,000		1.00		1,000,000
$	0.105		38,500,000		2.25		38,500,000
$	0.240		208,160		2.72		208,160
Total			98,158,160		2.67		98,158,160

Note 1 - Business Organization, Nature of Business and Basis of Presentation (Details Textual) - Series B Convertible Preferred Stock [Member]	Sep. 30, 2016 shares
Stock Issued During Period, Shares, Conversion of Convertible Securities	4,760,872
Sale of Stock, Percentage of Ownership after Transaction	65.00%

Note 8 - Common Stock, Preferred Stock, Warrants and Options - Option Activity (Details)	6 Months Ended
	Jun. 30, 2024 USD ($) $ / shares shares
Outstanding, options (in shares) \| shares	101,158,160
Outstanding, weighted average exercise price (in dollars per share) \| $ / shares	$ 0.059
Options exercised (in shares) \| shares	(3,000,000)
Options exercised, weighted average exercise price (in dollars per share) \| $ / shares	$ 0.024
Outstanding, options (in shares) \| shares	98,158,160
Outstanding, weighted average exercise price (in dollars per share) \| $ / shares	$ 0.06
Outstanding, weighted average remaining life (Year)	2 years 8 months 1 day
Outstanding, aggregate intrinsic value \| $	$ 0
Exercisable, options (in shares) \| shares	98,158,160
Exercisable, weighted average exercise price (in dollars per share) \| $ / shares	$ 0.06
Exercisable, weighted average remaining life (Year)	2 years 8 months 1 day
Exercisable, aggregate intrinsic value \| $	$ 0

Note 7 - Equity Incentive Plans

6 Months Ended

Jun. 30, 2024

Share-Based Payment Arrangement [Text Block]

Note 7 – Equity Incentive Plans

In January 2018, the Company’s 2018 Equity Incentive Plan (the “2018 EIP”) was established. The total number of shares of stock which may be purchased or granted directly by options, stock awards or restricted stock purchase offers, or purchased indirectly through exercise of options granted under the 2018 EIP shall not exceed fifteen million (15,000,000) shares. The shares are included in a registration statement filed January 2018. There were 0 shares available for issuance under the 2018 EIP as of June 30, 2024.

On September 30, 2021, the Board of Directors approved The Coretec Group, Inc. 2021 Equity Incentive Plan (“2021 EIP”) which covers the potential issuance of 62,000,000 shares of common stock, from which various awards may be granted, including but not limited to: (a) Incentive Stock Options, (b) Non-qualified Stock Options, (c) Stock Appreciation Rights, (d) Restricted Awards, I Performance Share Awards, and (f) Performance Cash Awards. There were 0 shares available for issuance under the 2021 EIP as of June 30, 2024.

On October 27, 2023, the Board of Directors approved The Coretec Group, Inc. 2023 Equity Incentive Plan (the “2023 Plan”), which covers the potential issuance of 57,000,000 shares of common stock, from which various awards may be granted, including but not limited to: (a) Incentive Stock Options, (b) Non-qualified Stock Options, (c) Stock Appreciation Rights, (d) Restricted Awards, I Performance Share Awards, and (f) Performance Cash Awards. There were 11,907,566 shares available for issuance under the 2023 EIP as of June 30, 2024.

Note 8 - Common Stock, Preferred Stock, Warrants, and Options (Details Textual)					3 Months Ended	6 Months Ended
	Mar. 02, 2021 USD ($) $ / shares shares	Oct. 22, 2020	Jun. 08, 2020 Rate shares	Oct. 04, 2019 $ / shares shares	Jun. 30, 2023 shares	Jun. 30, 2024 USD ($) $ / shares shares	Jun. 30, 2023 USD ($)	Dec. 31, 2023 $ / shares shares
Share Exchange Agreement, Number of Options Authorized			21,500,000
Share Exchange Agreement, Exchange Ratio \| Rate			60.00%
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exchanged						9,500,000
Stock Issued During Period, Shares, Stock Options Exchanged for Common Shares						5,700,000
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)								2,814,000
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) \| $ / shares						$ 0.0805		$ 0.0612
Share-Based Payment Arrangement, Expense \| $						$ 0	$ 0
Private Placement [Member]
Stock Issued During Period, Shares, New Issues	23,500,000
Proceeds from Issuance or Sale of Equity \| $	$ 6,000,000
Warrant Issued in Connection With Credit Agreement [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)				3,000,000		2,814,000
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) \| $ / shares				$ 0.052
Class of Warrant or Right, Number of Warrants Issued Per Dollar in the Event of Funding Deviation				1.2
Warrant Issued in Connection With Credit Agreement [Member] \| Minimum [Member]
Class of Warrant or Right, Issued Monthly				150,000
Warrant Issued in Connection With Credit Agreement [Member] \| Maximum [Member]
Class of Warrant or Right, Issued Monthly				210,000
Pre-funded Warrant [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)	51,500,000
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) \| $ / shares	$ 0.0001
Class of Warrant or Right, Purchase Price of Warrants or Rights \| $ / shares	$ 0.08
Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)	82,500,000
Class of Warrant or Right, Purchase Price of Warrants or Rights \| $ / shares	$ 0.0799
Placement Agent Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)	6,000,000
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) \| $ / shares	$ 0.1
Warrants Ownership Percentage, Maximum Limit	8.00%
S8 Common Stock [Member]
Common Stock Issued to Satisfy Accrued Liabilities, Discount Rate Used to Determine Number of Shares		50.00%
Common Stock Issued to Satisfy Accrued Liabilities, Number of Trading Days Over which Average Closing Price is Used to Determine Number of Shares		15
Stock Issued During Period, Shares, Satisfaction of Vendor Accrued Liabilities and Services					0	903,224

Note 7 - Equity Incentive Plans (Details Textual) - shares	Jun. 30, 2024	Oct. 27, 2023	Sep. 30, 2021	Jan. 31, 2018
2018 EIP [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized				15,000,000
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant	0
Equity Incentive Plan 2021 [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized			62,000,000
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant	0
The 2023 Equity Incentive Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized		57,000,000
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant	11,907,566

Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - $ / shares	Jun. 30, 2024	Dec. 31, 2023
Preferred Stock, Par or Stated Value Per Share (in dollars per share)	$ 0.0002	$ 0.0002
Preferred Stock, Shares Authorized (in shares)	500,000	500,000
Preferred Stock, Shares Outstanding, Ending Balance (in shares)	345,000	345,000
Preferred Stock, Shares Issued (in shares)	345,000	345,000
Common Stock, Par or Stated Value Per Share (in dollars per share)	$ 0.0002	$ 0.0002
Common Stock, Shares Authorized (in shares)	1,500,000,000	1,500,000,000
Common Stock, Shares, Issued (in shares)	336,738,361	284,104,032
Common Stock, Shares, Outstanding (in shares)	336,738,361	284,104,032

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Cash Flows from Operating Activities
Net loss	$ (858,447)	$ (981,679)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation	7,920	4,746
Amortization - intangibles	41,314	41,315
Amortization - debt discount	5,726	32,532
Change in:
Prepaid expenses	97,416	82,722
Prepaid warrant repurchase	250,000	(0)
Accounts payable and accrued liabilities	281,896	15,531
Net cash used in operating activities	(674,175)	(804,833)
Cash Flows from Investing Activities
Purchases of equipment	(0)	41,374
Cash Flows from Financing Activities
Payments on notes payable	(95,376)	(61,398)
Proceeds from exercised warrants	0	1,250
Proceeds from debt and - related party	250,000	0
Net cash provided by (used in) financing activities	154,624	(60,148)
Net change in cash	(519,551)	(906,355)
Cash, beginning of period	523,988	2,356,348
Cash, end of period	4,437	1,449,993
Cash paid during the period for interest	2,320	68,359
Non-Cash Financing Activities
Common stock issued to satisfy liabilities	$ 105,352	$ 18,087

Note 5 - Property, Plant and Equipment

6 Months Ended

Jun. 30, 2024

Property, Plant and Equipment Disclosure [Text Block]

Note 5 – Property, Plant and Equipment

The following table sets forth the tangible assets:

	June 30,			December 31,
	2024			2023
Laboratory equipment	$	127,191		$	127,191
Accumulated depreciation		(25,345	)		(17,425	)
Net property, plant and equipment	$	101,846		$	109,766

The Company’s laboratory equipment primarily consists of assets utilized for synthesis, battery manufacturing, testing and analysis.

Note 2 - Summary of Significant Accounting Policies (Details Textual) $ in Thousands	6 Months Ended
	Jun. 30, 2024 USD ($)
Goodwill, Impairment Loss	$ 0

Note 6 - Debt - Schedule of Debt (Details) - USD ($)	Jun. 30, 2024	Dec. 31, 2023	Aug. 31, 2023	Oct. 04, 2019
Notes payable, current portion	$ 1,346,075	$ 571,451
Current portion of long term debt	1,485,617	476,075
Current portion of long term debt	(1,485,617)	(476,075)
Total long term debt	$ 389,542	$ 1,003,816
Insurance Financing Agreement Due June 2024 [Member]
Debt Instrument, Interest Rate, Stated Percentage	8.29%	8.29%	8.29%
Notes payable, current portion	$ 0	$ 95,376
Current portion of long term debt	1,485,617	476,075
Notes payable - current	1,485,617	571,451
Current portion of long term debt	$ (1,485,617)	$ (476,075)
Credit Agreement And Note [Member]
Debt Instrument, Interest Rate, Stated Percentage	10.00%	10.00%		10.00%
10% promissory note, principal payments start July 2024	$ 1,346,075	$ 1,485,617
Warrants issued	0	(1,688)
Debt issuance costs	$ 0	$ (4,038)
Promissory Note Due December 2025 [Member]
Debt Instrument, Interest Rate, Stated Percentage	8.00%	8.00%
10% promissory note, principal payments start July 2024	$ 250,000

Note 9 - Commitments

6 Months Ended

Jun. 30, 2024

Commitments and Contingencies Disclosure [Text Block]

Note 9 – Commitments and Contingencies

Litigation, Claims, and Assessments

The Company may be involved in legal proceedings, claims and assessments arising in the ordinary course of business. In the opinion of management, such matters are currently not expected to have a material impact on the Company’s condensed consolidated financial statements. The Company records legal costs associated with loss contingencies as incurred and accrues for all probable and estimable settlements.

Warrant Purchase Agreement

On June 17, 2024, the Company entered into a Warrant Purchase Agreement with an Investor (the “Purchase Agreement”). Pursuant to the Purchase Agreement, the Company will purchase from the Investor all outstanding Warrants issued to the Investor, for an aggregate purchase price of $500,000. The Company paid an initial $250,000 to the Investor, included as a prepaid warrant repurchase in the condensed consolidated balance sheet, and has agreed to pay the Investor an additional payment of $250,000, if the Share Exchange transaction is successfully consummated (“Final Payment”). Following the delivery of the Final Payment to the Investors, the Investors will relinquish all rights, title and interest in the Warrants and assign the same to the Company, and the Warrants will be cancelled.

Real property leases

The Company is headquartered in Ann Arbor, Michigan where it is leasing office space and a wet laboratory, under gross lease terms. The office lease and wet laboratory leases were separate contracts. The annual rent obligation for the wet laboratory was $12,600 payable in equal monthly installments for the calendar years of 2022 and 2023. On December 15, 2023, the Company entered into a short renewal period for January 1, 2024 through April 30, 2024 under the same monthly financial terms. On May 1, 2022 the Company entered into an annual lease for dedicated office space. The annual office rent obligation was $42,000 payable in equal monthly installments. The company renewed this lease for the period of May 1, 2023 through April 30, 2024 under the same financial terms.

On February 1, 2024 the Company entered into an annual lease for a suite to house both wet laboratory space and administrative offices on the same business campus. The annual office rent obligation is $54,000 payable in equal monthly installments, under gross lease terms. The prior office lease also terminated on February 1, 2024 and the prior wet laboratory lease terminated on February 29, 2024.

Rent expense for the wet lab and office operating leases was $28,100 and $27,300 for the six months ended June 30, 2024 and 2023, respectively; and $13,500 and $13,650 for the three months ended June 30, 2024 and 2023, respectively.

Note 5 - Property, Plant and Equipment (Tables)

6 Months Ended

Jun. 30, 2024

Property, Plant and Equipment [Table Text Block]

	June 30,			December 31,
	2024			2023
Laboratory equipment	$	127,191		$	127,191
Accumulated depreciation		(25,345	)		(17,425	)
Net property, plant and equipment	$	101,846		$	109,766

Note 5 - Property, Plant and Equipment - Tangible Assets (Details) - USD ($)	Jun. 30, 2024	Dec. 31, 2023
Accumulated depreciation	$ (25,345)	$ (17,425)
Net property, plant and equipment	101,846	109,766
Equipment [Member]
Property, plant and equipment, gross	$ 127,191	$ 127,191

Note 4 - Intangibles (Details Textual) - Patents [Member]	Jun. 30, 2024 USD ($)
Finite-Lived Intangible Asset, Expected Amortization, Year One	$ 80,000
Finite-Lived Intangible Asset, Expected Amortization, Year Two	80,000
Finite-Lived Intangible Asset, Expected Amortization, Year Three	80,000
Finite-Lived Intangible Asset, Expected Amortization, Year Four	80,000
Finite-Lived Intangible Asset, Expected Amortization, Year Five	80,000
Finite-Lived Intangible Asset, Expected Amortization, after Year Five	$ 80,000

Note 2 - Summary of Significant Accounting Policies

6 Months Ended

Jun. 30, 2024

Business Description and Accounting Policies [Text Block]

Note 2 – Summary of Significant Accounting Policies

Principles of Consolidation

The consolidated financial statements include the accounts of the Group and its wholly owned subsidiary, Coretec. Intercompany transactions and balances have been eliminated in consolidation.

Use of Estimates

Intangibles

Goodwill

Property and Equipment

Estimated useful lives of property and equipment are as follows for the major classes of assets:

Asset Description	Estimated Lives (years)
Furniture and fixtures		7
Laboratory Equipment		7

Impairment of Long-Lived Assets

Fair Value of Financial Instruments

The following methods and assumptions were used to estimate the fair value of each class of financial instrument held by the Company:

Current assets and current liabilities - The carrying value approximates fair value due to the short maturity of these items.

Basic and Diluted Loss Per Common Share

	June 30,
	2024		2023
Options		98,158,160		77,158,160
Warrants		91,314,000		120,014,000
Series A convertible preferred stock		115,000		115,000
Convertible debt		123,280,537		45,155,537
Total potentially dilutive shares		312,867,697		242,442,697

Research and Development

Research and development costs are expensed as incurred.

Income Taxes

Note 6 - Debt - Principal Payment Schedule (Details)	Jun. 30, 2024 USD ($)
2024	$ 476,075
2025	870,000
2026	139,542
Long-Term Debt	$ 1,485,617